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Abstract
Background: Clinical trials are necessary for the advancement of cancer treatment and care, however low rates of
participation in such trials limit the generalisability of findings. The objective of this study was to examine the
proportion of medical oncology outpatients in Australia who are invited and consent to participate in clinical trials
and the factors associated with this.
Methods: A sample of adult medical oncology patients was recruited from three Australian cancer treatment
centres. Consenting patients completed two paper-and-pencil surveys; one at the time of consent and another
approximately 1 month later. A multivariate logistic regression was conducted to explore factors associated with
invitation and participation in a trial.
Results: Thirty-eight percent (n = 146) of the 383 participants reported they had been invited to take part in a
clinical trial. Of those invited, 93% reported consenting to participate in the trial, with the majority indicating that
they did not regret their decision (89%). Treatment centre and time since diagnosis were significantly associated
with being invited to take part in a clinical trial. None of the factors examined were associated with clinical trial
consent rates.
Conclusions: The main barrier to clinical trial participation is not being invited to do so, with the centre the patient
attends being a modifiable determinant of whether or not they are invited. Increasing the resources available to
treatment centres to ensure all patients are offered participation in trials they are eligible for may help to improve
rates of trial participation.
Keywords: Patient participation, Controlled clinical trials, Randomized, Neoplasms, Cancer, Informed consent,
Patient education
Background
Randomised clinical trials provide the strongest evidence
about whether a new treatment is better than an existing
treatment. While clinical trials are characterised by high
internal validity, they are often criticised as providing
poor evidence of external validity [1]. In order to maxi-
mise generalisability, high participant enrolment rates
must be achieved and the recruited sample must reflect
the diversity of the population to which the results will
be applied. However, only 2–3% of adult cancer patients
in the United States [2] and between 2 [3] and 11% [4]
of those in Australia are reported to participate in clin-
ical trials. This has led to cancer control organisations
reorganising clinical research infrastructure, setting tar-
gets and allocating dedicated resources in an effort to in-
crease trial participation [3, 5].
Several groups based on age, race, geographic location,
sex and socioeconomic status are under-represented in
cancer clinical trials. For example, while two thirds of
cancer patients are elderly, only 22–30% of clinical trial
participants are aged 65 years or over [6, 7]. Racial and
ethnic minority groups including African Americans,
Hispanics and Asian/Pacific Islanders are also less likely
to enrol in clinical trials [8]. Rural patients are signifi-
cantly less likely to be recruited than their urban coun-
terparts [9]. Men with colorectal cancer and lung cancer
are more likely than women with these diseases to
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participate in clinical trials [7]. Socioeconomic barriers are
also evident, with individuals of lower income and lower
education less likely to participate in clinical trials [10].
Clinical trials regularly close prior to meeting their re-
cruitment target, or take significantly longer than ex-
pected [11]. Low enrolment rates into clinical trials are
the result of a complex array of factors that operate at
the patient, clinician and systems levels [12]. Strict eligi-
bility criteria in clinical trials may make it less likely that
certain groups of patients may be eligible [13]. For ex-
ample, people with co-morbid conditions are often ex-
cluded from participation, contributing to low
enrolment rates among elderly people [14, 15]. Clinician
attitudes [16], including concerns related to the ethics of
randomisation [17], resource constraints such as insuffi-
cient staff or physical resources [4], and perceived pa-
tient burden [17] may influence willingness to enrol
patients in trials.
Organisational factors also play a role, with distance
between a clinician’s practice and the nearest clinical
trial centre inversely related to clinicians’ recruitment
rates to trials [18]. Not all hospitals are clinical trials ac-
tive. Non-academic medical centres also have lower pa-
tient recruitment rates due to limited clinical trials
infrastructure, workforce and diversity [5]. For trials tar-
geting uncommon cancers, patient availability may pose
challenges for achieving an adequate sample size [4].
Much of the evidence on biases in trial participation
among cancer patients has been derived in the United
States. It is not clear the extent to which these findings
are applicable to other countries. Australia has a univer-
sal health care system in which the government provides
free treatment at public hospitals, and subsidises the cost
of some prescription medicines. Therefore, financial bar-
riers to accessing treatment, and hence trials [10], may
be reduced in comparison to the USA context.
The aims of this study were to examine, among a sam-
ple of Australian medical oncology patients: 1) the pro-
portion who are invited to and agree to participate in a
clinical trial; 2) factors associated with a) being invited
to participate, and b) consenting to participate in a clin-
ical trial; 3) reasons for non-participation among those
who report not consenting to clinical trials; and 4) views
about who should determine whether patients are
approached to participate in multiple trials.
Methods
Setting
The current study was conducted as part of a larger
cross-sectional study examining psychological outcomes
among medical oncology patients. This study was con-
ducted in three cancer treatment centres in Australia.
Data were collected between November 2012 and Au-
gust 2014. All treatment centres were located in public
teaching hospitals with links to Universities and had a
clinical trials unit. Treatment centres A and C were lo-
cated in capital cities, while treatment centre B was lo-
cated in a major regional area. Treatment centres A and
B had 200–500 beds; while treatment centre C had more
than 500 beds. Ethics approvals were obtained from the
Human Research Ethics Committees of the University of
Newcastle, Cancer Institute of New South Wales, as well
as institutional ethics committees.
Participants
Patients who were aged 18 or older, diagnosed with can-
cer, English speaking and presenting for a medical oncol-
ogy outpatient appointment were eligible to participate.
Those attending the medical oncology clinic for the first
time, and those unable to provide informed consent due
to cognitive impairment or mental illness were excluded.
Procedure
A research assistant approached eligible patients in the
clinic to seek written informed consent. Consenting pa-
tients were asked to complete a paper and pencil survey
either in clinic or at home. Those who elected to take
the survey home were asked to return it within a week
in the reply paid envelope provided. This survey in-
cluded questions about sociodemographic, disease and
treatment variables, as well as questions about psycho-
logical wellbeing. Approximately 1 month later, a second
survey was mailed to participants. The questions on
clinical trial participation reported here were included in
the second survey. Up to two reminder letters were sent
to non-responders after 3 and 6 weeks.
Measures
Sociodemographic characteristics
Self-report data was collected on age, sex, highest level of
education, Aboriginal and/ or Torres Strait Islander status,
marital status, country of birth, home post code, living
situation, employment status, private health insurance sta-
tus, concession card status, and smoking status. In
Australia, concession cards are issued by the government
to low income earners to allow access to cheaper health
services and medications. Private health insurance pro-
vides cover to patients to be treated as a private patient in
a public or private hospital, by the doctor of their choice.
Disease and treatment variables
The following data were also collected by self-report:
cancer type, perceived stage of disease at diagnosis (early
versus advanced), perceived remission status, time since
diagnosis, current treatments (e.g surgery, chemotherapy
etc), and main reason for hospital visit on the day of re-
cruitment (e.g. to receive treatment, check-up after com-
pleting treatment, etc).
Carey et al. BMC Cancer  (2017) 17:653 Page 2 of 8
Participation in clinical trials
Participants were provided with the following definition
of a clinical trial to aid them in answering the questions:
“A clinical trial is a research study where participants
are assigned by chance (randomly) to receive the new
treatment or usual treatment.” Participants were asked
whether, since their cancer diagnosis, they had been in-
vited to take part in a clinical trial (yes/ no). Those who
responded “yes” were asked to indicate what the trial
was about using the following response options: “surgi-
cal treatments”, “radiation therapy”, “chemotherapy”,
“complementary therapy”, “psychological well-being”,
“can’t remember”, or “other”. More than one response
could be selected. Respondents were then asked whether
they had agreed to participate in the trial (yes/ no).
Views regarding trial participation
Those who had agreed to participate in a trial were
asked whether they would make the same choice again:
“Now that you think back, would you agree to take part
in the trial again?” (yes/no/not sure). Those who indi-
cated that they had declined to participate were asked to
indicate their reasons for non-participation from the fol-
lowing options: “I do not like the idea of clinical trials”,
“I wanted to choose my treatment”, “I did not under-
stand what was involved”, “I was worried about risks/
side effects”, “my loved ones did not want me to”, and
“other”.
Views regarding participation in multiple trials
Participants were given the following instructions: “Im-
agine that you are participating in a clinical trial and a
new trial comes up that you could participate in as well.
What should happen?” Response options included not
being asked about the second trial; the researcher check-
ing with the patient’s doctor first, and the patient being
asked directly if they wanted to participate. A copy of
the items assessing participation and views regarding
clinical trials is available as an Additional file 1.
Statistical analysis
Frequencies and percentages with 95% confidence in-
tervals were calculated for all variables of interest.
Characteristics of the sample (gender, cancer type and
age) were compared to national data using a one
sample chi-square test. Fisher’s exact test was used to
explore factors associated with being asked to partici-
pate in a trial. Those with a p-value <0.1 were in-
cluded in a multivariate exact logistic regression.
Odds ratios (95% confidence intervals) and exact p-
values were calculated. All statistical analyses were
programmed using SAS v9.4 [19].
Results
Of the 968 patients screened for eligibility, 179 (18%)
were ineligible. Of the 789 eligible patients, 605 (77%)
consented to take part in the study. Characteristics of
the 504 consenters who provided information on age
and sex were compared to non-consenters. There was a
higher proportion of females among consenters
(χ2 = 18.1, df = 2, p = 0.0001) and slightly higher propor-
tions of those aged 65+ for non-consenters (χ2 = 12.6,
df = 6, p = 0.0488). Three hundred and eighty-three pa-
tients (63%) completed both the baseline survey and
clinical trials questions and were included in the ana-
lyses. One hundred and fifty-two (40%) of these partici-
pants were recruited from treatment centre A; 111
(29%) from treatment centre B, and 120 (31%) from
treatment centre C.
Demographic and disease characteristics of the sample
are presented in Table 1. Comparison with national can-
cer incidence data [20] indicated that females were over-
represented in the current sample (χ2 = 48.28, df = 1,
p < .0001). The distribution of cancer types was also sig-
nificantly different to the national incidence data
(χ2 = 352.41, df = 5, p < .0001), with the current sample
having a greater proportion of breast and colorectal can-
cer patients and a lower proportion of prostate and mel-
anoma patients. There were no differences in the
proportion of those aged 65 and older between the
current sample and national data (χ2 = 0.04, df = 1,
p > .05).
Rates of clinical trial invitation by trial type
One hundred and forty six (38%; 95% CI = 33.23–43.0)
respondents reported that they had been invited to take
part in a clinical trial. The number of respondents who
had been invited by type of trial is shown in Table 2.
Eighteen (13%; 95% CI = 7.2–18.3) respondents reported
being invited to take part in more than one type of trial,
with the most common combination being radiation
therapy and chemotherapy trials (n = 7).
Rates of participation and reasons for non-participation
Of those who were invited to take part in a trial, 129
(93%; 95% CI =88.4–97.1) reported that they had con-
sented. That is, overall, 33% (95% CI =28.0–37.3) of the
sample reported having participated in clinical trial.
For the 17 respondents (11%; 95% CI =6.2–16.6) who
were invited but declined participation, ten provided rea-
sons for non-participation: ‘other’ reasons (n = 5) which
included accessibility, feeling too unwell to participate,
feeling that too much else was going on, and already be-
ing involved in a trial; wanting to choose own treatment
(n = 2); concern regarding risk factors and side effects
from participation (n = 2), and not liking the idea of
clinical trials (n = 1).
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Table 1 Sociodemographic, disease and treatment characteristics for participants who had and had not been invited to take part in
a clinical trial






Centre 1 74 (49%) 78 (51%) 0.0005
2 28 (25%) 83 (75%)
3 44 (37%) 76 (63%)
Age Less than 55 36 (34%) 69 (66%) 0.2089
55 to 74 90 (41%) 127 (59%)
75 and over 18 (31%) 41 (69%)
Gender Male 59 (41%) 84 (59%) 0.3290
Female 87 (36%) 153 (64%)
Aboriginal and/ or Torres Strait Islander Non indigenous 140 (37%) 234 (63%) 0.3701*
Indigenous 3 (60%) 2 (40%)
Marital Married/living with partner 92 (38%) 147 (62%) 0.7937
Single/divorced/separated/widowed 52 (37%) 88 (63%)
Education High school or less 76 (39%) 117 (61%) 0.5317
University or vocational 63 (36%) 111 (64%)
Country of birth Australia 105 (39%) 167 (61%) 0.6075
Other 39 (36%) 70 (64%)
Health insured Yes 65 (44%) 82 (56%) 0.0332
No 77 (33%) 154 (67%)
Concession card Yes 86 (37%) 147 (63%) 0.7000
No 56 (39%) 88 (61%)
Smoking status Current smoker 16 (37%) 27 (63%) 0.9513
Former smoker 65 (37%) 110 (63%)
Never smoked 62 (39%) 98 (61%)
Location of residence City/inner regional 119 (38%) 192 (62%) 0.9282
Outer regional/remote 26 (38%) 43 (62%)
Living arrangements With others 110 (37%) 184 (63%) 0.7784
Alone 34 (39%) 53 (61%)
Employment Full-time 26 (42%) 36 (58%) 0.1934
Part-time 15 (27%) 40 (73%)
All others 103 (39%) 159 (61%)
Time since diagnosis 12 m or less 51 (31%) 115 (69%) 0.0029
13 to 24 m 38 (54%) 32 (46%)
Over 24 m 57 (40%) 86 (60%)
Surgery No 39 (41%) 55 (59%) 0.4808
Yes 107 (37%) 179 (63%)
Chemotherapy No 25 (28%) 64 (72%) 0.0286
Yes 118 (41%) 170 (59%)
Radiotherapy No 45 (34%) 88 (66%) 0.4610
Yes 83 (38%) 137 (62%)
Hormone therapy No 92 (37%) 157 (63%) 0.6777
Yes 36 (35%) 68 (65%)
Biological therapy No 107 (34%) 205 (66%) 0.0341
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Of those who reported that they had agreed to partici-
pate, 112 respondents (89%; 95% CI = 83.3–94.4) said
that if asked to make the decision again that they would
still choose to participate.
Characteristics associated with being invited and
consenting to participate in a clinical trial
The univariate analysis showed that treatment centre,
private health insurance, time since diagnosis, remission,
chemotherapy and biological treatment were associated
with being asked to take part in a clinical trial (p < 0.1).
None of the factors examined were associated with the
decision to take part in a clinical trial (data not shown).
After adjusting for multiple variables, there was a signifi-
cant association between treatment centre, time since
diagnosis and being asked to take part in a clinical trial.
Participants from treatment centre B had increased odds
of being asked to participate in a trial compared to those
as centre A. The odds of being asked to participate in a
trial decreased with increasing time since diagnosis. All
other associations were found to be non-significant after
adjusting for confounders (Table 3).
Views on being approached to participate in multiple
trials
The majority of respondents (n = 91; 68%; 95% CI
=59.9–75.9) agreed that “I should be asked directly if I
want to participate in the second trial, and given the op-
tion to discuss it with my doctor if I want to.” Forty re-
spondents (30%; 95% CI =22.0–37.7) indicated “the
researcher should check if my doctor thinks I should
participate before discussing it with me”, while only 3
(2%; 95% CI =0.0–4.8) respondents said they “should not
be asked about the second trial”.
Discussion
Overall 33% of the sample reported having participated
in a clinical trial. This rate is very high compared to
other studies which have reported rates of participation
Table 1 Sociodemographic, disease and treatment characteristics for participants who had and had not been invited to take part in
a clinical trial (Continued)






Yes 21 (51%) 20 (49%)
Cancer stage at diagnosis Early 58 (32%) 124 (68%) 0.4376
Not applicable / Do not know 9 (45%) 11 (55%)
Progressed/advanced 21 (37%) 36 (63%)
Remission: Do not know 20 (29%) 48 (71%) 0.0306
In remission 24 (30%) 57 (70%)
Not in remission 66 (44%) 83 (56%)
Cancer type Haematological/blood cancer 5 (63%) 3 (38%) 0.3362
Breast 52 (33%) 108 (68%)
Colorectal 21 (38%) 35 (63%)
Prostate 11 (33%) 22 (67%)
Lung 13 (42%) 18 (58%)
Melanoma 7 (50%) 7 (50%)
More than one type or other 33 (45%) 41 (55%)
Reason for visit: combined To discuss treatment 20 (37%) 34 (63%) 0.9153
To receive treatment/check-up during treatment 60 (38%) 99 (62%)
Check-up after treatment/other 65 (40%) 99 (60%)
Note: Numbers for each category may not sum to 383 due to missing data. Percentages may not sum to 100 due to rounding
*p-value from exact tests
Table 2 Number and percentage of participants invited to take
part in a clinical trial by trial type
Trial type Total (n = 146) % (95% CI)
Surgical treatments 5 3.4 (0.4–6.4)
Radiation therapy 21 14 (8.6–20.1)
Chemotherapy treatments 73 50 (41.8–58.2)
Complementary or natural therapies 6 4.1 (0.8–7.4)
Psychological wellbeing 9 6.1 (2.2–10.1)
Cannot remember 17 11.6 (6.4–16.9)
Other 30 20.5 (13.9–27.2)
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in the range of 3 to 18% [4, 10, 21]. This may reflect that
our sample over-represented women with breast cancer
and people with colorectal cancer. A recent review
found representation of breast cancer in clinical trials is
proportionate to its incidence, whereas lung cancer has
the highest incidence and highest mortality (27.6%), but
accounts for only 9.2% of trials [22].
The overwhelming majority of those asked to partici-
pate in a trial reported that they had agreed to do so
(93%). This rate is higher than other studies that have
reported rates of acceptance into clinical cancer trials of
51–72% [21, 23]. Further, most reported that they would
make the same decision to participate in a clinical trial
again (89%). Together these results suggest that the big-
gest barrier to participation in a trial is not being invited
to do so. Due to the study methods, however, it was not
possible to determine the underlying reasons for not be-
ing invited to take part in a clinical trial. For example,
we do not know whether trials were available at the
treatment centres respondents attended, nor the eligibil-
ity of respondents for those trials. However, previous
studies show that even after patients are deemed eligible
by physicians and appropriate clinical trials for the can-
cer type and stage of disease are available, 40–50% of
cancer patients will still not be offered participation in a
trial [21].
Reasons reported for declining participation in a trial
were broadly consistent with past research. For example,
similar to our study, other research has indicated that
being overwhelmed, unwell, and preferring to choose
one’s own treatment rather than be randomised to a
treatment condition [15, 21, 23–25] as well as fear of
side effects [24] act as key barriers to participation.
Those diagnosed over 12 months ago were signifi-
cantly less likely to be invited to take part in a trial, with
the odds of being invited to participate decreasing with
increasing time since diagnosis. This may reflect that
more clinical trials are likely to be available for those
who are newly diagnosed. Therefore, as time since diag-
nosis increases, recall of invitations to participate in
trials during the early post-diagnosis period may de-
crease. The higher proportion of recently diagnosed
people who reported being asked to take part in trials
may also reflect the impact of national initiatives to in-
crease trial participation; and increasing recognition of
the critical role that clinical trials play in evidence-based
health care.
Treatment centre was the only other factor found to
be associated with being invited to participate in a trial
in the multivariable analysis. Those attending centre B
had 2.79 greater odds of having been invited to partici-
pate than those at treatment centre A. These results are
surprising given that treatment centre B was located in a
regional area rather than a large metropolitan area,
where greater research infrastructure and hence trial ac-
tivity might be expected. While only a small number of
treatment centres participated in the current study, re-
sults are consistent with previous reports suggesting
considerable variation in trial activity between centres
[5]. Previous research has reported that the number of
oncologists and the presence of an approved multidis-
ciplinary cancer program were significantly associated
with higher accrual to clinical trials [26], however, we
did not measure these characteristics.
In contrast to past research [21, 26–31], we found no
evidence that age, socioeconomic factors, or country of
birth were associated with being invited to participate in
a trial. It is possible that the lack of an association be-
tween country of birth and trial invitation was due to
the exclusion of non-English speakers from the sample.
There was also no association between cancer type and
trial invitation. This is at odds with other Australian re-
search which has identified a disproportionate number
of trials on breast cancer [32] and the relative rarity of
haematological cancer trials [4].
Implications
The treatment centre was a major determinant of being
asked to take part in a clinical trial. High acceptability of
trials was indicated by high reported consent rates and
Table 3 Factors associated with being asked to take part in a clinical trial as the outcome
Predictor Comparison OR (95% CI) Type 3 p-value
Centre B vs A 2.90 (1.27, 6.61) 0.0386
C vs A 1.93 (0.93, 4.01)
Private Health Insurance Yes vs No 0.73 (0.41, 1.29) 0.2759
Time Since Diagnosis 13 to 24 months vs 12 months or less 0.24 (0.11, 0.53) 0.0010
Over 24 months vs 12 months or less 0.46 (0.25, 0.87)
Chemotherapy treatment Yes vs No 0.65 (0.34, 1.24) 0.1873
Biological treatment Yes vs No 0.61 (0.27, 1.37) 0.2295
Remission Not in remission vs In remission 0.60 (0.30, 1.22) 0.2321
Do not know vs In remission 0.52 (0.23, 1.21)
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reported willingness to be offered the opportunity to
participate in more than one trial. Together these find-
ings suggest that one way to increase clinical trial par-
ticipation rates may be to upskill and/ or resource
hospitals with low rates of trial activity so that they can
actively recruit for a range of clinical trials. This may
have the advantage of ensuring equity of access to trials
for a broader range of patients as well as enabling more
rapid recruitment of the trial sample. However, if such
measures are to be effectively implemented it is likely
that some simplification to the complex multi-site ethics
processes that researchers face may be necessary. The
need to obtain multiple approvals and comply with a
range of organisation-specific requirements may act as a
significant barrier to expanding trial activity to a broader
range of institutions.
Limitations
The generalisability of our findings may be limited due to
the small number of centres that participated in our study,
and over-representation of women and those with breast
cancer. It is also possible that non-consenters to clinical tri-
als were under-represented in the sample. Further, transla-
tion of survey instruments into languages other than
English and provision of interpreter services were cost pro-
hibitive. Therefore, we had to exclude people who were not
fluent in English from participating. Lack of representation
of culturally and linguistically diverse populations within
our sample may have resulted in the prevalence of being
approached to participate in clinical trials being overesti-
mated. Given these limitations, further investigation of our
findings in a larger and more diverse sample of treatment
centres and patients is warranted.
Data regarding trial participation was self-reported by
respondents. While a clear definition was provided about
what participation in a clinical trial constituted, it is pos-
sible that participants did not accurately recall these dis-
cussions with their healthcare providers.
Data on clinical and treatment variables were based on
patient self-report due to the prohibitive cost of extracting
this information from hospital medical records. One study
comparing the accuracy of self-reported disease and treat-
ment among 895 women with breast cancer to medical re-
cords data, showed that for general questions about
whether the person had had surgery, chemotherapy, radio-
therapy or hormone treatment), accuracy was very high
(100%, 99%, 99 and 94% respectively) [33]. Agreement
about whether a recurrence had occurred was also high at
90%; while agreement regarding stage at diagnosis was
lower at 60%. This suggests that most self-reported data
about basic cancer disease and treatment information is
likely to be accurate.
Finally, although few cancer patients receive all of their
cancer care at one treatment centre, we did not assess
whether participants were invited to and participated in
a trial at the treatment centre from which they were re-
cruited. The inclusion of this information in future sur-
veys may help to clarify the role that treatment centre
plays in clinical trial access.
Conclusions
The biggest modifiable determinant of access to a clinical a
trial is the treatment centre. Higher rates of accrual to clinical
cancer trials may be achieved by increasing the resources
available to healthcare providers to ensure all eligible patients
are offered participation in appropriate trials.
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